

Pierre Larochelle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10715177/publications.pdf>

Version: 2024-02-01

40
papers

3,027
citations

257357

24
h-index

345118

36
g-index

40
all docs

40
docs citations

40
times ranked

3153
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	0.8	431
2	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	0.8	400
3	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	0.8	221
4	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy. Canadian Journal of Cardiology, 2010, 26, 249-258.	0.8	191
5	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	0.8	173
6	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	0.8	163
7	Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. Journal of Hypertension, 2006, 24, 1405-1412.	0.3	139
8	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.	0.8	127
9	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II "Therapy. Canadian Journal of Cardiology, 2006, 22, 583-593.	0.8	113
10	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy. Canadian Journal of Cardiology, 2009, 25, 287-298.	0.8	111
11	The atrial natriuretic factor: Its physiology and biochemistry. Reviews of Physiology, Biochemistry and Pharmacology, 1988, 110, 1-145.	0.9	92
12	Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. Journal of Hypertension, 1998, 16, 1357-1369.	0.3	87
13	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy. Canadian Journal of Cardiology, 2007, 23, 539-550.	0.8	87
14	An emerging relationship between peripheral sympathetic nervous activity and atrial natriuretic factor. Life Sciences, 1987, 40, 1545-1551.	2.0	86
15	Role of Tumor Necrosis Factor- α Gene Locus in Obesity and Obesity-Associated Hypertension in French Canadians. Hypertension, 2000, 36, 14-19.	1.3	82
16	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy. Canadian Journal of Cardiology, 2008, 24, 465-475.	0.8	78
17	The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Canadian Journal of Cardiology, 2005, 21, 657-72.	0.8	56
18	The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Canadian Journal of Cardiology, 2002, 18, 625-41.	0.8	44

#	ARTICLE	IF	CITATIONS
19	Unreliability of Home Blood Pressure Measurement and the Effect of a Patient-Oriented Intervention. Canadian Journal of Cardiology, 2015, 31, 658-663.	0.8	43
20	Comparative Assessment of Four Blood Pressure Measurement Methods in Hypertensives. Canadian Journal of Cardiology, 2011, 27, 455-460.	0.8	40
21	Hypertension in people with type 2 diabetes: Update on pharmacologic management. Canadian Family Physician, 2011, 57, 997-1002, e347-53.	0.1	37
22	Hypertension in diabetes: A call to action. Canadian Journal of Cardiology, 2009, 25, 299-302.	0.8	32
23	Effect of metoclopramide on plasma catecholamine release in essential hypertension. Clinical Pharmacology and Therapeutics, 1985, 37, 372-375.	2.3	28
24	Effects of Valsartan or Amlodipine Alone or in Combination on Plasma Catecholamine Levels at Rest and During Standing in Hypertensive Patients. Journal of Clinical Hypertension, 2007, 9, 168-178.	1.0	28
25	Single-dose pharmacokinetics of ¹⁴ C-lovastatin in chronic renal failure. Clinical Pharmacology and Therapeutics, 1991, 50, 437-441.	2.3	23
26	Responses to tyramine and norepinephrine after imipramine and trazodone. Clinical Pharmacology and Therapeutics, 1979, 26, 24-30.	2.3	21
27	Attenuation of Autonomic Nervous System Functions in Hypertensive Patients at Rest and During Orthostatic Stimulation. Journal of Clinical Hypertension, 2008, 10, 97-104.	1.0	17
28	The Gap Between Manual and Automated Office Blood Pressure Measurements Results at a Hypertension Clinic. Canadian Journal of Cardiology, 2017, 33, 653-657.	0.8	16
29	Basis of false-positive glucagon tests for pheochromocytoma. Clinical Pharmacology and Therapeutics, 1981, 29, 687-694.	2.3	12
30	Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial. Blood Pressure, 2008, 17, 170-177.	0.7	12
31	Renal Effects of Immersion in Essential Hypertension. American Journal of Hypertension, 1994, 7, 120-128.	1.0	11
32	Treatment of Hypertension. Canadian Journal of Diabetes, 2013, 37, S117-S118.	0.4	10
33	Does QTc Interval Predict the Response to β -Blockers and Calcium Channel Blockers in Hypertensives?. Heart Disease (Hagerstown, Md), 2003, 5, 244-252.	1.3	9
34	Clinical Relationships of Cyclic GMP. Advances in Pharmacology, 1994, 26, 305-319.	1.2	4
35	The impact of unrecorded readings on the precision and diagnostic performance of home blood pressure monitoring: a statistical study. Journal of Human Hypertension, 2018, 32, 197-202.	1.0	2
36	Effect of aminoglycosides on the disposition of thyroid hormones and thyroglobulin. Clinical Pharmacology and Therapeutics, 1985, 38, 686-691.	2.3	1

#	ARTICLE	IF	CITATIONS
37	From Family to Pharmacogenetics. <i>Public Health Genomics</i> , 2000, 3, 112-115.	0.6	0
38	Confirming the critical importance of blood pressure control in people with diabetes. <i>Canadian Journal of Cardiology</i> , 2009, 25, 594-595.	0.8	0
39	Traitement de lâ€™hypertension. <i>Canadian Journal of Diabetes</i> , 2013, 37, S492-S493.	0.4	0
40	Hypertension revisited. <i>Canadian Family Physician</i> , 2012, 58, 634-6.	0.1	0